Literature DB >> 27497531

Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy.

Katarzyna Rojek1, Eric Nickels1, Barbara Neistadt1, Rafael Marquez1, Amittha Wickrema1, Andrew Artz1, Koen van Besien1, Richard A Larson1, Ming K Lee2, Jeremy P Segal3, Mary-Claire King2, Tom Walsh2, Akiko Shimamura4, Sioban B Keel5, Jane E Churpek6, Lucy A Godley7.   

Abstract

Analysis of the clinical characteristics of hematopoietic stem cell transplant (HSCT) donors has proven beneficial for identifying cases of heritable hematopoietic disorders. This study examines poor peripheral blood hematopoietic stem cell mobilization after granulocyte colony-stimulating factor administration among 328 donors as a potential marker for suspected familial predisposition to myeloid malignancies. Here, we present data comparing the clinical characteristics of poor-mobilizing versus nonpoor-mobilizing donors and the results of panel-based sequencing of hematopoietic genes in poor-mobilizing donors. From this analysis, we identified a novel case of a donor-derived myelodysplastic syndrome in an HSCT recipient that is consistent with clonal evolution of TET2-mutated clonal hematopoiesis of indeterminate potential (CHIP) within the donor. This study demonstrates the potential risk of using hematopoietic stem cells from a donor with CHIP and raises the question of whether there should be increased screening measures to identify such donors.
Copyright © 2016 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clonal hematopoiesis of indeterminate potential; Donor-derived leukemia; TET2 mutation

Mesh:

Substances:

Year:  2016        PMID: 27497531      PMCID: PMC5592729          DOI: 10.1016/j.bbmt.2016.08.002

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  8 in total

1.  Effects of granulocyte-colony-stimulating factor on Monosomy 7 aneuploidy in healthy hematopoietic stem cell and granulocyte donors.

Authors:  Matthew J Olnes; Andrea Poon; Susan J Miranda; Loretta Pfannes; Zachary Tucker; Kelsey Loeliger; Hesed Padilla-Nash; Yu Ying Yau; Thomas Ried; Susan F Leitman; Neal S Young; Elaine M Sloand
Journal:  Transfusion       Date:  2011-08-29       Impact factor: 3.157

2.  Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia.

Authors:  Jane E Churpek; Eric Nickels; Rafael Marquez; Katarzyna Rojek; Bohao Liu; Rachelle Lorenz; Janet Lepore; Jozef Madzo; Amittha Wickrema; Andrew S Artz; Koen van Besien; Lucy A Godley
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113

3.  Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure.

Authors:  Tom J Vulliamy; Amanda Walne; Aroon Baskaradas; Philip J Mason; Anna Marrone; Inderjeet Dokal
Journal:  Blood Cells Mol Dis       Date:  2005 May-Jun       Impact factor: 3.039

4.  Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity.

Authors:  Michael Y Zhang; Siobán B Keel; Tom Walsh; Ming K Lee; Suleyman Gulsuner; Amanda C Watts; Colin C Pritchard; Stephen J Salipante; Michael R Jeng; Inga Hofmann; David A Williams; Mark D Fleming; Janis L Abkowitz; Mary-Claire King; Akiko Shimamura
Journal:  Haematologica       Date:  2014-09-19       Impact factor: 9.941

5.  Age-related clonal hematopoiesis associated with adverse outcomes.

Authors:  Siddhartha Jaiswal; Pierre Fontanillas; Jason Flannick; Alisa Manning; Peter V Grauman; Brenton G Mar; R Coleman Lindsley; Craig H Mermel; Noel Burtt; Alejandro Chavez; John M Higgins; Vladislav Moltchanov; Frank C Kuo; Michael J Kluk; Brian Henderson; Leena Kinnunen; Heikki A Koistinen; Claes Ladenvall; Gad Getz; Adolfo Correa; Benjamin F Banahan; Stacey Gabriel; Sekar Kathiresan; Heather M Stringham; Mark I McCarthy; Michael Boehnke; Jaakko Tuomilehto; Christopher Haiman; Leif Groop; Gil Atzmon; James G Wilson; Donna Neuberg; David Altshuler; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

6.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

Review 7.  Donor cell leukemia: a review.

Authors:  Daniel H Wiseman
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-15       Impact factor: 5.742

8.  Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA.

Authors:  Patrick F Fogarty; Hiroki Yamaguchi; Adrian Wiestner; Gabriela M Baerlocher; Elaine Sloand; Weihua S Zeng; Elizabeth J Read; Peter M Lansdorp; Neal S Young
Journal:  Lancet       Date:  2003-11-15       Impact factor: 79.321

  8 in total
  14 in total

1.  Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias.

Authors:  Christopher J Gibson; James A Kennedy; Sarah Nikiforow; Frank C Kuo; Edwin P Alyea; Vincent Ho; Jerome Ritz; Robert Soiffer; Joseph H Antin; R Coleman Lindsley
Journal:  Blood       Date:  2017-04-26       Impact factor: 22.113

2.  Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies.

Authors:  Michael W Drazer; Sabah Kadri; Madina Sukhanova; Sushant A Patil; Allison H West; Simone Feurstein; Dalein A Calderon; Matthew F Jones; Caroline M Weipert; Christopher K Daugherty; Adrián A Ceballos-López; Gordana Raca; Mark W Lingen; Zejuan Li; Jeremy P Segal; Jane E Churpek; Lucy A Godley
Journal:  Blood Adv       Date:  2018-01-23

3.  How I diagnose and manage individuals at risk for inherited myeloid malignancies.

Authors: 
Journal:  Blood       Date:  2016-07-28       Impact factor: 22.113

Review 4.  Therapy-related myeloid neoplasms: when genetics and environment collide.

Authors:  Megan E McNerney; Lucy A Godley; Michelle M Le Beau
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

Review 5.  Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome.

Authors:  Lacey Williams; Kimberley Doucette; Judith E Karp; Catherine Lai
Journal:  Bone Marrow Transplant       Date:  2021-03-08       Impact factor: 5.483

Review 6.  Germline Genetic Predisposition to Hematologic Malignancy.

Authors:  Elissa Furutani; Akiko Shimamura
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

Review 7.  Familial myelodysplastic syndrome/acute myeloid leukemia.

Authors:  Jane E Churpek
Journal:  Best Pract Res Clin Haematol       Date:  2017-10-04       Impact factor: 3.020

Review 8.  Hereditary Myelodysplastic Syndrome and Acute Myeloid Leukemia: Diagnosis, Questions, and Controversies.

Authors:  Imo J Akpan; Afaf E G Osman; Michael W Drazer; Lucy A Godley
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

9.  Clonal Hematopoiesis in Related Allogeneic Transplant Donors: Implications for Screening and Management.

Authors:  Matthew D Seftel; Michelle Kuxhausen; Linda Burns; Pintip Chitphakdithai; Dennis Confer; Deirdre Kiefer; Stephanie Lee; Brent Logan; Paul O'Donnell; Michael Pulsipher; Nirali N Shah; Galen Switzer; Bronwen E Shaw
Journal:  Biol Blood Marrow Transplant       Date:  2020-03-05       Impact factor: 5.742

Review 10.  Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia.

Authors:  Robert P Hasserjian; David P Steensma; Timothy A Graubert; Benjamin L Ebert
Journal:  Blood       Date:  2020-05-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.